Ascend Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

Ascend Capital’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-225,000	Closed	-$2.07M	–	194
2016 Q4	$2.07M	Buy	+225,000	New	+$2.54M	0.1%	120

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCP

Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ascend Capital's INSY Position: Q1 2017 in Review

Ascend Capital sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 225,000 shares — an estimated $2.07M sold.

Ascend Capital first reported a position in INSY in Q4 2016 and held it in 1 quarter. The position peaked at $2.07M in Q4 2016. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

Ascend Capital reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Ascend Capital sold 225,000 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $2.07M.
Ascend Capital first reported a position in Insys Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
Ascend Capital's Insys Therapeutics, Inc. position peaked at $2.07M in Q4 2016.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on Ascend Capital's 13F filing for Q1 2017, filed 15 May 2017.